Diagnosis and management of rare gastrointestinal lymphomas

References

• Otter R, Bieger R, Kluin PM, . Primary gastrointestinal non-Hodgkin's lymphoma in a population-based registry. Br J Cancer 1989;60:745–750.
   PubMed Web of Science ®Google Scholar
• Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252–260.
   PubMed Web of Science ®Google Scholar
• Rohatiner A, d'Amore F, Coiffier B, . Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994;5:397–400.
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Catassi C, Fabiani E, Corrao G, . Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002;287:1413–1419.
   PubMed Web of Science ®Google Scholar
• Card TR, West J, Holmes GK. Risk of malignancy in diagnosed coeliac disease: a 24-year prospective, population-based, cohort study. Aliment Pharmacol Ther 2004;20:769–775.
   PubMed Web of Science ®Google Scholar
• Ilyas M, Niedobitek G, Agathanggelou A, . Non-Hodgkin's lymphoma, coeliac disease, and Epstein-Barr virus: a study of 13 cases of enteropathy-associated T- and B-cell lymphoma. J Pathol 1995;177:115–122.
   PubMed Web of Science ®Google Scholar
• Dube C, Rostom A, Sy R, . The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 2005;128:S57–S67.
   PubMed Web of Science ®Google Scholar
• Al-Toma A, Verbeek WH, Hadithi M, . Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007;56: 1373–1378.
   PubMed Web of Science ®Google Scholar
• Ashton-Key M, Diss TC, Pan L, . Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am J Pathol 1997;151:493–498.
   PubMed Web of Science ®Google Scholar
• Verbeek WH, Van De Water JM, Al-Toma A, . Incidence of enteropathy-associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. Scand J Gastroenterol 2008;43:1322–1328.
   PubMed Web of Science ®Google Scholar
• Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005;128:S79–S86.
   PubMed Web of Science ®Google Scholar
• Levine MS, Rubesin SE, Pantongrag-Brown L, . Non-Hodgkin's lymphoma of the gastrointestinal tract: radiographic findings. AJR Am J Roentgenol 1997;168:165–172.
   PubMed Web of Science ®Google Scholar
• Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol 1992;141:1361–1371.
   PubMed Web of Science ®Google Scholar
• d'Amore F, Brincker H, Gronbaek K, . Non-Hodgkin's lymphoma of the gastrointestinal tract: a population-based analysis of incidence, geographic distribution, clinicopathologic presentation features, and prognosis. Danish Lymphoma Study Group. J Clin Oncol 1994;12:1673–1684.
   PubMed Web of Science ®Google Scholar
• Domizio P, Owen RA, Shepherd NA, . Primary lymphoma of the small intestine. A clinicopathological study of 119 cases. Am J Surg Pathol 1993;17:429–442.
   PubMed Web of Science ®Google Scholar
• Swerdlow S, Campo E, Harris NL, . WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. pp. 214–217.
   Google Scholar
• Hadithi M, Mallant M, Oudejans J, . 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 2006;47:1622–1627.
   PubMed Web of Science ®Google Scholar
• Al-Toma A, Verbeek WH, Visser OJ, . Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma. Dig Liver Dis 2007;39:634–641.
   PubMedGoogle Scholar
• Egan LJ, Walsh SV, Stevens FM, . Celiac-associated lymphoma. A single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol 1995;21:123–129.
   PubMed Web of Science ®Google Scholar
• Gale J, Simmonds PD, Mead GM, . Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000;18:795–803.
   PubMed Web of Science ®Google Scholar
• Novakovic BJ, Novakovic S, Frkovic-Grazio S: A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep 2006;16: 191–195.
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Angamuthu N, Boyd K, . Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115:3664–3670.
   PubMed Web of Science ®Google Scholar
• Bishton MJ, Lush RJ, Byrne JL, . Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007;136:752–761.
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Prince HM, . Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011;117:5827–5834.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, . Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. Blood 2010;116(Suppl. 1): Abstract 114.
   Google Scholar
• Piekarz RL, Frye R, Turner M, . Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27: 5410–5417.
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre MF, Kim EJ, . Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485–4491.
   PubMed Web of Science ®Google Scholar
• Jiang L, Yuan CM, Hubacheck J, . Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 2009;145:173–179.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Patti C, . Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316–2323.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Nakase H, Yamashita K, . Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol 2010;45: 370–388.
   PubMed Web of Science ®Google Scholar
• Shia J, Teruya-Feldstein J, Pan D, . Primary follicular lymphoma of the gastrointestinal tract: a clinical and pathologic study of 26 cases. Am J Surg Pathol 2002;26:216–224.
   PubMed Web of Science ®Google Scholar
• Yoshino T, Miyake K, Ichimura K, . Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 2000;24: 688–693.
   PubMed Web of Science ®Google Scholar
• Schmatz AI, Streubel B, Kretschmer-Chott E, . Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol 2011;29:1445–1451.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780–2795.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, . Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A, . Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003;362:516–522.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Nakase H, Yamashita K, . Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol 2010;45:370–388.
   PubMed Web of Science ®Google Scholar
• Bende RJ, Smit LA, van Noesel CJ. Molecular pathways in follicular lymphoma. Leukemia 2007;21:18–29.
   PubMed Web of Science ®Google Scholar
• Bende RJ, Smit LA, Bossenbroek JG, . Primary follicular lymphoma of the small intestine: alpha4beta7 expression and immunoglobulin configuration suggest an origin from local antigen-experienced B cells. Am J Pathol 2003;162:105–113.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clnical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. v.1.2010. Available from: http://www.24hmb.com/UpLoad/Editor/2010/1/4/2010010471345169.pdf
   Google Scholar
• Dreyling M. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl. 5):v181–v183.
   Google Scholar
• Salles G, Seymour JF, Offner F, . Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377:42–51.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, . Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295–3301.
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Li S, Neuberg D, . Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 2006;64:928–934.
   PubMed Web of Science ®Google Scholar
• Eich HT, Heimann M, Stutzer H, . Long-term outcome and prognostic factors in early-stage nodal low-grade non-Hodgkin's lymphomas treated with radiation therapy. Strahlenther Onkol 2009;185:288–295.
   PubMed Web of Science ®Google Scholar
• Kodama M, Kitadai Y, Shishido T, . Primary follicular lymphoma of the gastrointestinal tract: a retrospective case series. Endoscopy 2008;40:343–346.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Medeiros LJ, Hagemeister FB, . Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003;97:586–591.
   PubMed Web of Science ®Google Scholar
• Salar A, Juanpere N, Bellosillo B, . Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006;30:1274–1280.
   PubMed Web of Science ®Google Scholar
• Oinonen R, Franssila K, Teerenhovi L, . Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998;34:329–336.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, . A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Ruskone-Fourmestraux A, Delmer A, Lavergne A, . Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D'etude des Lymphomes Digestifs. Gastroenterology 1997;112:7–16.
   PubMed Web of Science ®Google Scholar
• Moller MB, Pedersen NT, Christensen BE. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. Br J Haematol 2006;133:43–49.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, . SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555–1562.
   PubMed Web of Science ®Google Scholar
• Fernandez V, Salamero O, Espinet B, . Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Hosein PJ, Pastorini VH, Paes FM, . Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol 2011;86:841–845.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, . Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677–2684.
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, . Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706–714.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans JC, Hoster E, Vehling-Kaiser U, . Rituximab maintenance significantly prolongs duration of remission in elderly patients with mantle cell lymphoma. Haematologica 2011;96(Suppl. 2): Abstract 504.
   Google Scholar
• Suzuki R, Suzumiya J, Yamaguchi M, . Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann Oncol 2010;21:1032–1040.
   PubMed Web of Science ®Google Scholar
• Wong KF, Chan JK, Cheung MM, . Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 2001;115:266–270.
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY, . Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004;103:216–221.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH, . Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612–618.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Yokoyama M, Ishizawa S, . Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation. Blood 2010;116:5631–5637.
   PubMed Web of Science ®Google Scholar
• Mansoor A, Pittaluga S, Beck PL, . NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood 2011;117:1447–1452.
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Huh J, . Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res 2007;13: 3250–3254.
   PubMed Web of Science ®Google Scholar
• Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005;19:2186–2194.
   PubMed Web of Science ®Google Scholar
• Khong PL, Pang CB, Liang R, . Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann Hematol 2008;87:613–621.
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, . Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 2004;104:243–249.
   PubMed Web of Science ®Google Scholar
• Koom WS, Chung EJ, Yang WI, . Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys 2004;59:1127–1137.
   PubMed Web of Science ®Google Scholar
• Li YX, Yao B, Jin J, . Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181–189.
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, . Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002;54: 182–190.
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI, . Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000;18:54–63.
   PubMed Web of Science ®Google Scholar
• Lee SH, Ahn YC, Kim WS, . The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma. Haematologica 2006;91:427–428.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS, . Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for Improving Survival of Lymphoma study. J Clin Oncol 2009;27:6027–6032.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Anderson BO, Advani R, . Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009;10: 1093–1101.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kita K, Miwa H, . Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351–2356.
   PubMed Web of Science ®Google Scholar
• Nagafuji K, Fujisaki T, Arima F, . L-asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 2001;74:447–450.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Nomura K, Kanda-Akano Y, . Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 2003;44:879–882.
   PubMed Web of Science ®Google Scholar
• Jaccard A, Petit B, Girault S, . L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009;20:110–116.
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhang Y, . L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003;78:163–167.
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Kwong YL, Kim WS, . Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal Natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol 2011;29:4410–4416.
   PubMed Web of Science ®Google Scholar